Hsbc Holdings PLC Sells 747 Shares of SI-BONE, Inc. (NASDAQ:SIBN)

Hsbc Holdings PLC reduced its stake in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 2.7% during the 2nd quarter, Holdings Channel.com reports. The firm owned 26,886 shares of the company’s stock after selling 747 shares during the quarter. Hsbc Holdings PLC’s holdings in SI-BONE were worth $343,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of SI-BONE by 24.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,649 shares of the company’s stock valued at $138,000 after purchasing an additional 2,108 shares during the last quarter. Arizona State Retirement System grew its stake in shares of SI-BONE by 9.0% during the second quarter. Arizona State Retirement System now owns 10,921 shares of the company’s stock valued at $141,000 after purchasing an additional 903 shares during the last quarter. Assenagon Asset Management S.A. bought a new stake in shares of SI-BONE during the second quarter valued at approximately $152,000. RiverPark Advisors LLC boosted its stake in SI-BONE by 260.4% in the first quarter. RiverPark Advisors LLC now owns 11,357 shares of the company’s stock valued at $186,000 after acquiring an additional 8,206 shares during the last quarter. Finally, EntryPoint Capital LLC boosted its stake in SI-BONE by 78.4% in the first quarter. EntryPoint Capital LLC now owns 13,906 shares of the company’s stock valued at $228,000 after acquiring an additional 6,113 shares during the last quarter. 98.11% of the stock is owned by institutional investors.

SI-BONE Trading Down 0.1 %

SIBN opened at $13.60 on Thursday. The firm’s fifty day moving average is $15.02 and its two-hundred day moving average is $14.71. The company has a debt-to-equity ratio of 0.22, a quick ratio of 8.12 and a current ratio of 9.17. The firm has a market cap of $560.39 million, a PE ratio of -12.48 and a beta of 1.22. SI-BONE, Inc. has a twelve month low of $11.76 and a twelve month high of $22.56.

SI-BONE (NASDAQ:SIBN) last posted its earnings results on Monday, August 5th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.04. The company had revenue of $39.97 million for the quarter, compared to analyst estimates of $38.95 million. SI-BONE had a negative net margin of 27.10% and a negative return on equity of 24.27%. During the same period last year, the business posted ($0.30) earnings per share. Equities research analysts anticipate that SI-BONE, Inc. will post -0.89 EPS for the current year.

Analysts Set New Price Targets

SIBN has been the topic of a number of recent research reports. Needham & Company LLC reduced their price objective on shares of SI-BONE from $27.00 to $19.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Morgan Stanley reduced their price objective on shares of SI-BONE from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Finally, Truist Financial reduced their price objective on shares of SI-BONE from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $23.00.

Insider Activity at SI-BONE

In related news, CEO Laura Francis sold 9,967 shares of the business’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $13.84, for a total value of $137,943.28. Following the sale, the chief executive officer now directly owns 492,923 shares of the company’s stock, valued at approximately $6,822,054.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Laura Francis sold 9,967 shares of the stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $13.84, for a total transaction of $137,943.28. Following the completion of the transaction, the chief executive officer now directly owns 492,923 shares in the company, valued at $6,822,054.32. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Anthony J. Recupero sold 3,905 shares of the stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $13.84, for a total value of $54,045.20. Following the transaction, the insider now owns 238,804 shares of the company’s stock, valued at $3,305,047.36. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 21,714 shares of company stock valued at $304,997. 5.40% of the stock is owned by corporate insiders.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.